Highlights

  • Epiminder shares rose 6.33% to AUD 0.42 on 1 June 2026 following an update on its DETECT clinical study.
  • The company announced the enrolment of the 25th patient in its US-based DETECT trial evaluating the Minder System.
  • A total of 19 clinical sites across the United States are now participating in the study, including centres affiliated with Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania.
  • Epiminder remains on track to reach 50 enrolled patients in mid-Q3 CY2026 and continues targeting 210 participants by the end of the first half of CY2027.

Epiminder Ltd (ASX:EPI) attracted investor attention on 1 June 2026 after announcing a key milestone in its DETECT clinical study, with shares rising 6.33% to AUD 0.42 during the session. While the stock remains down 67.94% over the past year, the latest update appeared to provide investors with encouragement as the company reported continued progress in a clinical program that forms a central part of its commercialisation strategy.

The company confirmed that the DETECT (Diagnosing Epilepsy To EffeCT change) study has now enrolled its 25th patient, marking another step forward in the evaluation of its FDA-authorised Minder System. Management noted that the milestone was achieved in line with the timeline previously communicated to shareholders and reflects growing recruitment activity across participating US clinical sites.

About Epiminder

Epiminder is a medical device and information solutions company focused on developing technologies designed to improve the diagnosis and management of epilepsy and other seizure-related conditions that require continuous monitoring.

Founded in 2017 through collaboration involving Professor Mark Cook, the Bionics Institute, St Vincent’s Hospital, the University of Melbourne and Cochlear Limited, the company has developed the Minder System, an implantable continuous EEG monitoring platform designed to provide long-term objective data on brain activity.

Headquartered in Melbourne, Epiminder also maintains operations in the United States and has positioned the DETECT study as a significant component of its strategy to expand clinical adoption and support broader commercial access to its technology.

25th Patient Enrolment Marks Important Clinical Milestone

The company's latest announcement centred on the successful enrolment of the 25th participant in the DETECT study, a prospective, randomised, controlled, blinded, multi-centre clinical trial being conducted across the United States.

The study is evaluating the Minder System as a tool to assist clinicians in making treatment and diagnostic decisions for epilepsy patients who have undergone prolonged electroencephalographic (EEG) monitoring without obtaining a conclusive result.

Management described the achievement as an important milestone within the company's broader commercialisation roadmap.

Chief Executive Officer Rohan Hoare noted that reaching 25 enrolled patients was a target previously communicated to investors and highlighted the continued expansion of participating clinical sites as an important Factor supporting future recruitment.

The enrolment milestone was achieved in accordance with the timeline outlined during Epiminder's February 2026 investor presentation, demonstrating progress against previously stated operational objectives.

For investors, the update provides evidence that the study continues to advance according to plan, while also supporting the company's efforts to generate clinical evidence that may assist future reimbursement discussions and wider clinical adoption.

Expanding Network of Leading US Clinical Sites

A notable feature of the DETECT study is the calibre and breadth of participating medical centres.

Epiminder reported that 19 clinical sites across the United States are now actively participating in the trial. These sites include institutions affiliated with Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania, among other recognised epilepsy centres.

The growing number of participating sites is expected to play an important role in supporting patient recruitment as the study progresses.

The company indicated that ongoing site activation activities remain underway and are expected to contribute to continued enrolment momentum.

With recruitment activity increasing, management remains focused on achieving its next major milestone of 50 enrolled patients, which is currently expected during the middle of the third quarter of calendar year 2026.

The expansion of participating centres not only increases recruitment capacity but also broadens the study's reach across different patient populations and clinical settings.

Addressing a Significant Challenge in Epilepsy Care

According to the company, DETECT has been designed to address a widely recognised challenge faced by epilepsy patients and clinicians.

Many patients undergo prolonged monitoring in specialised epilepsy monitoring units (EMUs) in an attempt to capture and analyse seizure activity. However, a substantial proportion of these monitoring stays do not produce definitive results.

Epiminder noted that between 30% and 50% of inpatient epilepsy monitoring unit assessments are considered inconclusive. For many patients, this can create uncertainty regarding diagnosis, seizure classification and treatment planning.

The inability to capture seizure events during conventional monitoring may delay access to therapies and further clinical intervention.

The Minder System has been developed to address this issue by enabling long-term continuous monitoring outside the hospital environment.

Unlike conventional monitoring methods that are often limited to relatively short observation periods, the Minder platform continuously records bilateral subscalp EEG data over extended periods, potentially allowing neurologists to capture seizure activity that may not occur during a brief inpatient stay.

The company believes that access to longer-term objective electrographic information may assist clinicians in reaching more informed decisions regarding diagnosis and treatment pathways.

Understanding the DETECT Study Design

The DETECT study has been structured to evaluate whether extended EEG monitoring can provide clinically actionable information for patients who have previously received inconclusive monitoring results.

The trial is designed to enrol up to 210 participants across as many as 25 clinical sites throughout the United States.

Participants will undergo a six-month primary follow-up period as part of the study.

The primary endpoint focuses on the proportion of participants who achieve what the study defines as an actionable clinical event.

These outcomes may include confirmation of a diagnosis, seizure classification, assessment for epilepsy surgery, identification of psychogenic nonepileptic seizures (PNES), or other clinically meaningful determinations that influence patient management.

The company views these endpoints as particularly important because they are directly linked to clinical decision-making and patient care pathways.

By generating evidence around these outcomes, Epiminder aims to demonstrate the practical Utility of the Minder System within real-world epilepsy management.

Minder System Positioned at the Centre of Commercialisation Strategy

The DETECT study is more than a clinical research program for Epiminder. It represents a key element of the company's commercialisation plans.

Management has consistently highlighted the importance of generating clinical evidence that can support broader adoption of the technology and facilitate reimbursement pathways.

The Minder System has already received authorisation from the US Food and Drug Administration through the de novo pathway, allowing it to be used as a marketed device within the DETECT post-market study.

The system consists of a minimally invasive implantable continuous EEG monitoring device that records brain activity over extended periods. Data are transmitted through an external wearable device and smartphone application to a secure cloud-based platform.

Patients can continue their normal daily activities while being monitored, enabling the collection of long-term neurological information in real-world environments over months or even years.

The company believes this capability differentiates the technology from conventional short-duration EEG monitoring approaches.

Additional Research Supports Long-Term Monitoring Approach

Alongside the DETECT update, Epiminder also highlighted a recently published research paper in the Journal Epilepsia.

According to the company, the publication provides additional evidence supporting the feasibility of subscalp EEG technology as a reliable long-term monitoring solution.

The announcement follows earlier results from the UMPIRE first-in-human multicentre trial, which was published in Epilepsia in 2025 and evaluated the safety and signal quality of the Minder platform during extended monitoring periods.

While the DETECT study remains focused on demonstrating clinical utility and decision-making benefits, these research publications contribute to the broader body of evidence supporting the technology.

What This Means for Investors

Epiminder's latest update represents another operational milestone within a clinical program that sits at the centre of its commercialisation strategy.

The achievement of the 25-patient enrolment target demonstrates continued progress against management's previously stated timelines while highlighting growing participation across leading US epilepsy centres.

Investors will likely continue monitoring recruitment trends as the company works toward its next milestone of 50 enrolled patients expected in mid-Q3 CY2026. Attention is also likely to remain focused on the broader target of enrolling 210 patients by the end of the first half of CY2027.

With the DETECT study designed to generate clinical evidence supporting reimbursement and broader adoption of the Minder System, future enrolment updates and study progress may remain key areas of interest for shareholders evaluating the company's long-term commercial objectives.